Cincinnati, Cleveland and Columbus: The three Cs of a venture boom in flyover country.
San Francisco-based accelerator IndieBio focuses on helping bring new bio-engineered products to market, like milk and eggs.
Life science investing is seeing a boom as drug companies deliver products that match their promise.
The Apple Watch could be a home run product for the company and third-party developers and their backers. But it may not happen in the first generation.
Nokia makes first investment in sector as corporate funds aim to jump into driver’s seat.
Matt Oguz of Palo Alto Venture Science is aiming to raise a $200 million fund to make bets based on the data, not the gut.
The human brain may be complicated, but more VCs are finding it easy to back drug developers focused on neurological conditions
Enthusiasm surrounding the impending IPO of the e-commerce company is breaking the ice for surging U.S. activity in fast-growing China.